Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › daratumumab

daratumumab

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of daratumumab

33 trials tracked of daratumumab: 8 in phase 3 or 4 and 7 with published results. The most-cited published study has 968 citations.

33Trials tracked
8Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 3 8 Phase 2 25
  1. Phase 3 A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Completed · 968 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis Completed · 687 cited
  3. Phase 3 Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Completed · 429 cited
  4. Phase 3 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex Completed · 336 cited
  5. Phase 3 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Completed · 137 cited
  6. Phase 3 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Completed · 130 cited
Show 27 more trials
  1. Phase 3 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Completed · 127 cited
  2. Phase 3 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma Completed
  3. Phase 2 A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia Completed
  4. Phase 2 Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment Completed
  5. Phase 2 A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type Completed
  6. Phase 2 Daratumumab in Treatment of PGNMID and C3 GN Completed
  7. Phase 2 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Completed
  8. Phase 2 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Completed
  9. Phase 2 Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma Completed
  10. Phase 2 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Completed
  11. Phase 2 A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread Completed
  12. Phase 2 Short Course Daratumumab in Patients With Multiple Myeloma Completed
  13. Phase 2 Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Completed
  14. Phase 2 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma Completed
  15. Phase 2 Daratumumab in Treating Patients With Multiple Myeloma Completed
  16. Phase 2 A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma Completed
  17. Phase 2 A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma Completed
  18. Phase 2 A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Completed
  19. Phase 2 A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Completed
  20. Phase 2 Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Completed
  21. Phase 2 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  22. Phase 2 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Completed
  23. Phase 2 A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  24. Phase 2 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis Completed
  25. Phase 2 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting Completed
  26. Phase 2 Daratumumab for the Treatment of Patients With AL Amyloidosis Completed
  27. Phase 2 A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed

Showing the 33 most-cited and recently-updated of 33 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
D-VCd improves hematologic CR rate to 59.5% compared to 19.2% in AL amyloidosis
Oncology RCT
D-VCd improves hematologic CR rate to 59.5% compared to 19.2% in AL amyloidosis Trial shows adding daratumumab improves outcomes for AL amyloidosis
This Phase 3 randomized controlled trial of 388 patients with newly diagnosed AL amyloidosis found that adding subcutaneous daratumumab to V…
Adding daratumumab to a standard drug combination helps patients with AL amyloidosis achieve faster and deeper responses in blood and organ …
Blood Aug 28, 2026
Daratumumab improves progression-free survival in patients with cytogenetically high-risk multiple myeloma
Allergy & Immunology Meta-analysis
Daratumumab improves progression-free survival in patients with cytogenetically high-risk multiple myeloma Daratumumab shows significant progress for high risk multiple myeloma
This meta-analysis evaluated the impact of daratumumab on progression-free survival in patients with cytogenetically high-risk multiple myel…
A new analysis shows that the drug daratumumab significantly slows the progression of high risk multiple myeloma in patients.
Frontiers Aug 27, 2026
D-VRd ranks highest for progression-free survival among anti-CD38 regimens in transplant-ineligible multiple myeloma
Allergy & Immunology Meta-analysis
D-VRd ranks highest for progression-free survival among anti-CD38 regimens in transplant-ineligible multiple myeloma New data ranks best treatments for transplant-ineligible multiple myeloma
This network meta-analysis of 6 trials involving 3162 patients evaluated various treatment nodes for transplant-ineligible newly diagnosed m…
A large review of 3,162 patients reveals which combinations of drugs work best to keep multiple myeloma from progressing.
Frontiers Aug 24, 2026
Reduced-dose daratumumab and bortezomib may achieve partial renal remission in CyBorD-refractory PGNMID
Rheumatology Guideline
Reduced-dose daratumumab and bortezomib may achieve partial renal remission in CyBorD-refractory PGNMID Reduced Dose Daratumumab Shows Promise for Rare Kidney Disease
This case report describes a 73-year-old male with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) who ach…
A new case report shows a reduced dose of daratumumab may help manage severe kidney disease and heart failure in high-risk elderly patients.
Frontiers Aug 16, 2026
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Allergy & Immunology Sys. Review
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Cochrane Apr 10, 2026
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis
Hematology Cohort
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis Small study links daratumumab resistance to immune changes in light-chain amyloidosis
An observational cohort study of 30 patients with primary light-chain amyloidosis treated with daratumumab-bortezomib-dexamethasone found th…
Patients with weaker responses to amyloidosis treatment showed lower gene activity before therapy and increased immune stress during treatme…
medRxiv Apr 6, 2026
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Hematology Phase II
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…
CT.gov Mar 30, 2026